MetaVia is trading 8.4% higher in pre-market at $1.67, rebounding from its October 1 close of $1.54. - No clear company-specific announcement dated October 2 was identified in the company’s press-release listings. - The latest listed releases include its August 6 second-quarter results and September preclinical findings. - Major U.S. indices are indicated higher, but there is not enough evidence to attribute MetaVia’s move to a specific catalyst.